pipette
ENEnglish

FibriLysins disrupt Staphylococcus aureus biofilms and abscess communities

Vincent De Maesschalck, Marco Chittò, Claudia Siverino, Lena Gens, Stephan Zeiter, Alisa Hangartner, Sandrine Harzé, Eliane Vanhoffelen, Camille Van Laere, Alison Kerremans, Marleen Voet, Maarten Boon, Tine Van Win, Greetje Vande Velde, Jeroen Wagemans, Willem‐Jan Metsemakers, Robert Geoff Richards, T. Fintan Moriarty, Rob Lavigne

Revista con revisión por paresUso en el mundo real

En palabras de los autores

Abstract The rise of antibiotic resistance, particularly among pathogens such as methicillin-resistant Staphylococcus aureus , necessitates innovative antibacterial strategies. Here we introduce FibriLysins, a class of engineered enzymes combining staphylokinase and endolysin, which dismantle fibrin-encapsulated multicellular staphylococcal communities, including biofilms and staphylococcal abscess communities (SACs). We characterized diverse staphylokinases, developing a library of 27 FibriLysins, with a 78% positive hit rate. The lead variant, FL-028, has significant antibacterial activity against prevalent clinical S. aureus isolates. In vitro, FL-028 reduced bacterial counts in SACs by 3.4 log and in biofilms by 2.3 log. In vivo, FL-028 exhibits superior efficacy in a mouse model of bone fracture-related infection, outperforming vancomycin by 1 log and eliminating SAC presence in tissues. FL-028 shows no adverse effects on bone healing, as confirmed by histological examination, mechanical testing and micro-computed tomography analyses. These preclinical findings highlight the potential of FibriLysins as a robust and safe therapeutic approach against difficult-to-treat staphylococcal infections.

Resultado principalEl resumen no menciona limitaciones.

Apareció: domingo, 25 de octubre. Nature Microbiology. Revista con revisión por pares.

DOI: 10.1038/s41564-026-02513-1